Table 1.

Characteristics of 84 women tested for quantitation of HPV-16 DNA

VariableNo. (%) womenVariable value
Age
    Age categories (y)
        10-205 (6.0)
        20-2935 (41.7)
        30-3928 (33.3)
        40-4913 (15.5)
        50-590 (0.0)
        60-701 (1.2)
        Unknown2 (2.4)
    Average (y)31.4 ± 8.5
    Median (y)30.4
    Range (y)18-63.3
HIV infection status
    HIV seronegative18 (21.4)
    HIV seropositive66 (78.6)
CD4 cell count (cells/μL) measured for 66 women
    <20021 (31.8)
    200-40028 (42.4)
    >40015 (22.7)
    CD4 not tested2 (3.0)
    Average304 ± 209
    Median262
    Range6-960
Ethnicity
    Caucasian62 (73.8)
    African descent14 (16.7)
    Asian4 (4.8)
    First Nation2 (2.4)
    Unknown2 (2.4)
Smoking
    Current smoker40 (47.6)
    Not currently smoking44 (52.4)
HAART in 66 HIV-positive women
    HAART during HPV-16 infection23 (34.9)
    No HAART during HPV-16 infection43 (65.1)
Age at first intercourse
    Age categories (y)
        10.1-122 (2.4)
        12.1-1419 (22.6)
        14.1-1626 (31.0)
        16.1-1820 (23.8)
        18.1-209 (10.7)
        >203 (3.6)
        Unknown5 (4.0)
    Average (y)16.1 ± 2.3
    Median (y)16.0
    Range (y)12.0-22.0
Detection of HPV types other than 16
    Present94 (65.3)
    Absent50 (34.7)
Cytology smear results at 144 visits
    Normal77 (53.5)
    ASCUS5 (3.5)
    LSIL24 (16.7)
    HSIL8 (5.5)
    Unsatisfactory1 (0.7)
    Not done29 (20.1)
Colposcopy and histology results
    Normal9 (10.7)
    CIN-112 (14.3)
    CIN-27 (8.3)
    CIN-33 (4.8)
    Not done52 (61.9)
HPV-16 LCR phylogenetic lineage
    European57 (67.9)
    African 16 (7.1)
    African 23 (3.0)
    Asian American3 (3.0)
    Not done15 (17.9)
HPV-16 E6 phylogenetic lineage
    European56 (66.6)
    African9 (10.2)
    Asian American3 (3.0)
    Not done16 (19.0)
HPV-16 E6 variations
    E6 prototype49 (58.3)
    E6 nonprototype19 (22.6)
    Not done16 (19.0)
  • NOTE: Averages are means ± 1 SD.

    Abbreviations: ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions; HAART, highly active antiretroviral therapy.